Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Hemophilia A

ClinicalTrials.gov lists 783 trials for Hemophilia A or a narrower condition beneath it. Novo Nordisk A/S has the most among industry and government lead sponsors, with 68.

MeSH D006467 Hemic and Lymphatic Diseases C15 C16 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 81 Phase 1/2 Phase 1/2 23 Phase 2 Phase 2 34 Phase 2/3 Phase 2/3 15 Phase 3 Phase 3 139 Phase 4 Phase 4 67 Not applicable Not applicable 120 Observational Observational 303 Phase 1 Phase 1 81 Phase 1/2 Phase 1/2 23 Phase 2 Phase 2 34 Phase 2/3 Phase 2/3 15 Phase 3 Phase 3 139 Phase 4 Phase 4 67 Not applicable Not applicable 120 Observational Observational 303

Trials per phase (log scale)

1 more section with rows

783 of the 783 trials are tagged with Hemophilia A itself; the rest are tagged with a narrower condition beneath it.

Get the Hemophilia A report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Hemophilia A trials start? (33)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 4 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 54

1990: 1 trials (Observational 1) 1994: 1 trials (Not applicable 1) 1995: 1 trials (Observational 1) 1997: 1 trials (Phase 4 1) 1998: 1 trials (Observational 1) 1999: 2 trials (Observational 2) 2000: 2 trials (Not applicable 2) 2001: 6 trials (Observational 1, Phase 4 1, Phase 3 2, Phase 2/3 2) 2002: 7 trials (Observational 4, Phase 2/3 1, Phase 2 1, Phase 1 1) 2003: 6 trials (Observational 1, Not applicable 1, Phase 4 2, Phase 3 2) 2004: 7 trials (Observational 3, Phase 3 3, Phase 2/3 1) 2005: 14 trials (Observational 3, Not applicable 3, Phase 4 3, Phase 3 1, Phase 2 2, Phase 1 2) 2006: 12 trials (Observational 1, Not applicable 2, Phase 4 5, Phase 3 2, Phase 2/3 1, Phase 2 1) 2007: 5 trials (Observational 1, Phase 4 2, Phase 3 1, Phase 2 1) 2008: 13 trials (Observational 5, Phase 4 3, Phase 3 2, Phase 2 2, Phase 1 1) 2009: 30 trials (Observational 10, Not applicable 3, Phase 4 5, Phase 3 5, Phase 2 2, Phase 1 5) 2010: 25 trials (Observational 7, Not applicable 2, Phase 4 2, Phase 3 4, Phase 2/3 1, Phase 2 4, Phase 1 5) 2011: 22 trials (Observational 9, Not applicable 2, Phase 3 6, Phase 1 5) 2012: 31 trials (Observational 8, Not applicable 5, Phase 4 1, Phase 3 6, Phase 2/3 3, Phase 1 8) 2013: 18 trials (Observational 6, Phase 4 2, Phase 3 8, Phase 2/3 1, Phase 1 1) 2014: 41 trials (Observational 19, Not applicable 5, Phase 4 3, Phase 3 8, Phase 2 1, Phase 1 5) 2015: 48 trials (Observational 24, Not applicable 6, Phase 4 3, Phase 3 6, Phase 2 1, Phase 1/2 2, Phase 1 6) 2016: 37 trials (Observational 18, Not applicable 5, Phase 4 2, Phase 3 8, Phase 1 4) 2017: 34 trials (Observational 13, Not applicable 5, Phase 4 2, Phase 3 4, Phase 2 4, Phase 1/2 3, Phase 1 3) 2018: 54 trials (Observational 21, Not applicable 10, Phase 4 3, Phase 3 10, Phase 2 4, Phase 1/2 3, Phase 1 3) 2019: 34 trials (Observational 13, Not applicable 3, Phase 4 2, Phase 3 7, Phase 2 1, Phase 1/2 3, Phase 1 5) 2020: 51 trials (Observational 23, Not applicable 12, Phase 4 4, Phase 3 6, Phase 2/3 1, Phase 2 1, Phase 1/2 2, Phase 1 2) 2021: 53 trials (Observational 18, Not applicable 13, Phase 4 4, Phase 3 10, Phase 1/2 1, Phase 1 7) 2022: 41 trials (Observational 14, Not applicable 6, Phase 4 7, Phase 3 5, Phase 2 2, Phase 1/2 2, Phase 1 5) 2023: 41 trials (Observational 15, Not applicable 6, Phase 4 2, Phase 3 8, Phase 2/3 1, Phase 2 3, Phase 1/2 4, Phase 1 2) 2024: 51 trials (Observational 23, Not applicable 12, Phase 4 2, Phase 3 5, Phase 2/3 1, Phase 2 2, Phase 1/2 1, Phase 1 5) 2025: 37 trials (Observational 16, Not applicable 5, Phase 4 3, Phase 3 6, Phase 2/3 2, Phase 2 1, Phase 1 4)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 40
2025 37
2024 51
2023 41
2022 41
2021 53
2020 51
2019 34
2018 54
2017 34

Showing 10 of 33 earlier years.

Start your 14-day trial Email me all 33 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 48 trials starting in 2026 and about 42 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 46 trials still running at the 2026-10-09 snapshot; registered median of 20 months across 509 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Hemophilia A trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 81
Phase 1/2 23
Phase 2 34
Phase 2/3 15
Phase 3 139
Phase 4 67
Not applicable 120
Observational 303
Expanded access 1

How many Hemophilia A trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 30
Recruiting 73
Enrolling by invitation 11
Active, not recruiting 34
Completed 464

Showing 5 of 10 statuses.

Start your 14-day trial Email me all 10 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Hemophilia A trials? (13)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Novo Nordisk A/S 68
Bayer 56
Baxalta now part of Shire 40
Pfizer 34
Investigación en Hemofilia y Fisioterapia 20

Showing 5 of 13 sponsors.

Start your 14-day trial Email me all 13 sponsors as a PDF

Which drugs are being tested for Hemophilia A? (13)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
ADVATE 36
Emicizumab 26
Moroctocog alfa 19
Turoctocog alfa 18
PEGylated Recombinant Factor VIII 15

Showing 5 of 13 drugs.

Start your 14-day trial Email me all 13 drugs as a PDF

Interventions as named in the registry (2)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Recombinant Factor VIII (50 IU/kg) 19
No treatment given 10

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Hemophilia A trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Factor VIII inhibition 150 18
Haemarthrosis 73 27
Fall 51 21
Anti factor VIII antibody positive 49 9
Haemophilic arthropathy 45 10

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Hemophilia A? (638)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Safety and Use of Eptacog Beta 225 µg/kg in Patients With Haemophilia A or B With Inhibitors. Haemophilia : the official journal of the World Federation of Hemophilia 2025 Yes
Long-term safety and efficacy of fitusiran prophylaxis, and perioperative management, in people with hemophilia A or B. Blood advances 2025 Yes
Perioperative Management With Efanesoctocog Alfa in Patients With Haemophilia A in the Phase 3 XTEND-1 and XTEND-Kids Studies. Haemophilia : the official journal of the World Federation of Hemophilia 2025 Yes
A Global Cross-Sectional Database Study of Low Dose FVIII SHL Prophylaxis in Haemophilia A. Haemophilia : the official journal of the World Federation of Hemophilia 2025 Yes
Estimated Long-Term Durability of Valoctocogene Roxaparvovec Treatment in Male patients with Severe Hemophilia A: An Extrapolation of Clinical Data. Advances in therapy 2025 Yes

Showing 5 of 638 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (330)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Hemophilia A Point prevalence 1-5 / 10 000 United Kingdom GB Exact
Hemophilia A Point prevalence 1-5 / 10 000 United Kingdom GB Exact
Hemophilia A Point prevalence 1-5 / 10 000 United Kingdom GB Unspecified
Hemophilia A Point prevalence 1-9 / 100 000 United States US Unspecified
Hemophilia A Point prevalence 1-9 / 100 000 United States US Exact

Showing 5 of 330 prevalence observations.

Start your 14-day trial Email me the first 50 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Hemophilia A 98878 Exact Orphanet Rare Disease Ontology (ORDO)
Hemophilia A 98878 Exact Orphadata Science knowledge files, Product 1

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: sub-conditions in mesh.

Browse all condition evidence pages